Kardigan disclosed on Thursday that it is pursuing an initial public offering in the United States with a target valuation of up to $1.4 billion. The company indicated it intends to offer 23.3 million shares at a proposed price range of $14 to $16 per share, which would raise as much as $373.3 million if the top end of the range is achieved.
The company is a clinical-stage biotechnology firm focused on precision therapies for cardiovascular disease. Kardigan is advancing three late-stage experimental candidates: danicamtiv, which is being developed for genetic dilated cardiomyopathy; ataciguat, aimed at calcific aortic valve stenosis; and tonlamarsen, which targets hepatic angiotensinogen for blood pressure control in acute severe hypertension.
Headquartered in Princeton, New Jersey, the company plans to list its shares on the Nasdaq stock exchange under the ticker symbol "KARD." The underwriting group for the transaction includes J.P. Morgan, Jefferies, Leerink Partners and TD Cowen.
Summary of the offering and strategic focus:
- Kardigan has set a valuation target of up to $1.4 billion for its proposed U.S. IPO.
- The proposed share sale is 23.3 million shares at $14 to $16 per share, with potential gross proceeds up to $373.3 million.
- The company is a clinical-stage developer of precision cardiovascular medicines, with three late-stage experimental therapies in its pipeline.
The filing presents the company's capital plan and clinical focus without additional commentary on timing or use of proceeds. The information released identifies the therapeutic programs by name and clinical objective but does not include further trial results or regulatory milestones in this disclosure.
With established investment banks named as underwriters, the company has positioned the offering to list on a major U.S. exchange. The listing plan and specified ticker are included in the filing details.
This report is based solely on the information disclosed in the company's filing related to the proposed offering.